| Expression of osteoclast differentiation signals by stromal elements of giant cell tumors GJ Atkins, DR Haynes, SE Graves, A Evdokiou, S Hay, S Bouralexis, ... Journal of Bone and Mineral Research 15 (4), 640-649, 2000 | 231 | 2000 |
| Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL‐induced apoptosis A Evdokiou, S Bouralexis, GJ Atkins, F Chai, S Hay, M Clayer, DM Findlay International journal of cancer 99 (4), 491-504, 2002 | 195 | 2002 |
| Death to the bad guys: targeting cancer via Apo2L/TRAIL S Bouralexis, DM Findlay, A Evdokiou Apoptosis 10, 35-51, 2005 | 177 | 2005 |
| Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone GJ Atkins, S Bouralexis, DR Haynes, SE Graves, SM Geary, A Evdokiou, ... Bone 28 (4), 370-377, 2001 | 121 | 2001 |
| Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis A Evdokiou, A Labrinidis, S Bouralexis, S Hay, DM Findlay Bone 33 (2), 216-228, 2003 | 114 | 2003 |
| IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice JMW Quinn, NA Sims, H Saleh, D Mirosa, K Thompson, S Bouralexis, ... The Journal of Immunology 181 (8), 5720-5729, 2008 | 103 | 2008 |
| Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy S Bouralexis, DM Findlay, GJ Atkins, A Labrinidis, S Hay, A Evdokiou British journal of cancer 89 (1), 206-214, 2003 | 99 | 2003 |
| The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL LM Butler, V Liapis, S Bouralexis, K Welldon, S Hay, LM Thai, A Labrinidis, ... International journal of cancer 119 (4), 944-954, 2006 | 72 | 2006 |
| Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis GJ Atkins, S Bouralexis, A Evdokiou, S Hay, A Labrinidis, ACW Zannettino, ... Bone 31 (4), 448-456, 2002 | 72 | 2002 |
| Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro A Nakamura, C Ly, M Cipetić, NA Sims, J Vieusseux, V Kartsogiannis, ... Bone 40 (2), 305-315, 2007 | 46 | 2007 |
| Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone A Evdokiou, GJ Atkins, S Bouralexis, S Hay, LJ Raggatt, PA Cowled, ... International journal of oncology 19 (3), 625-632, 2001 | 35 | 2001 |
| Apo2l/Tumor necrosis factor–related apoptosis-inducing ligand prevents breast cancer–induced bone destruction in a mouse model LM Thai, A Labrinidis, S Hay, V Liapis, S Bouralexis, K Welldon, ... Cancer research 66 (10), 5363-5370, 2006 | 34 | 2006 |
| Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo S Zopf, D Neureiter, S Bouralexis, T Abt, KB Glaser, K Okamoto, ... International journal of oncology 31 (6), 1391-1402, 2007 | 31 | 2007 |
| Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: A potential new approach using TRAIL M Clayer, S Bouralexis, A Evdokiou, S Hay, GJ Atkins, DM Findlay Journal of Orthopaedic Surgery 9 (2), 19-22, 2001 | 31 | 2001 |
| Thai le M, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer … LM Butler, V Liapis, S Bouralexis, K Welldon, S Hay Int J Cancer 119 (4), 944-954, 2006 | 23 | 2006 |
| Thai le M, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer … LM Butler, V Liapis, S Bouralexis, K Welldon, S Hay Int J Cancer 119 (4), 944-954, 2006 | 23 | 2006 |
| Calcitonin decreases the adherence and survival of HEK-293 cells by a caspase-independent mechanism DM Findlay, LJ Raggatt, S Bouralexis, S Hay, GJ Atkins, A Evdokiou Journal of endocrinology 175 (3), 715-726, 2002 | 23 | 2002 |
| Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin S Bouralexis, M Clayer, GJ Atkins, A Labrinidis, S Hay, S Graves, ... International journal of oncology 24 (5), 1263-1270, 2004 | 21 | 2004 |
| PTHrP overexpression increases sensitivity of breast cancer cells to Apo2L/TRAIL V Cheung, S Bouralexis, MT Gillespie PloS one 8 (6), e66343, 2013 | 13 | 2013 |
| Gamma-tocotrienol triggers caspase-mediated induction of apoptosis in androgen-responsive, but not androgen unresponsive prostate cancer cells in vitro AD Odysseos, P Vraka, S Bouralexis, DM Frindlay, A Papas, A Evdokiou FREE RADICAL RESEARCH 36, 116-118, 2002 | 8 | 2002 |
